Hematology Drugs
Prescription drugs and medicines for conditions and diseases relating to blood and blood-forming. Studies in this area include: anemia, blood clots, bone marrow transplant, leukemia, platelet disorders, red-cell disorders, T-cell lymphoma, vitamin deficiencies, white-cell disorders, and others.
The list of FDA approved drugs for hematology and blood conditions appears below. Click any link to view the full drug information.
Treatment for Paget's Disease
For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma
Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke
Treatment for thrombocythemia
Treatment for the prevention and control of bleeding in subjects with hemophilia
Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
Injectable solution for the prevention of deep vein thrombosis
For the treatment of chronic lymphocytic leukemia
For the prevention of peri-operative and peri-partum thromboembolic events
Treatment for hemophilia B
Treatment for hemophilia B
For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse
For the treatment of Ph+ chronic myelogenous leukemia
For use in combination for the treatment of leukemia
For the treatment of both treatment-na?ve and -experienced Myelodysplastic Syndromes
Treatment for sickle-cell anemia
for the prevention of thrombotic cardiovascular complications in acute coronary syndromes
For the treatment of Gaucher disease
For the management of plasma uric acid levels in adults with malignancies
For the treatment of acute lymphoblastic leukemia
For the treatment of iron deficiency anemia associated with chronic kidney disease
For the treatment of transfusional iron overload due to thalassemia
For the treatment of iron deficiency anemia.
For the treatment of peripheral T-cell lymphoma
Treatment of prophylaxis of deep vein thrombosis (DVT)
Treatment for mastocytosis
Treatment for severe Hypoglycemia
Treatment for blood-glucose lowering
Generic version of Glynase PresTab
For the treatment of acute symptomatic deep vein thrombosis
For the treatment of cutaneous T-cell lymphoma
For the treatment of myelofibrosis
For the treatment of hemophilia A
For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria
For the treatment of multiple myeloma
Treatment for the replenishment of white blood cells
For the treatment of erectile dysfunction related to sexual activity in men
Treatment for prevention of blood clots following hip-replacement surgery
Treatment for acute deep vein thrombosis
For the treatment of Ph- acute lymphoblastic leukemia
For the treatment of anemia associated with chronic renal failure
For the treatment of non-Hodgkin?s lymphoma and multiple myeloma
Treatment for vitamin B-12 deficiency
Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy
Treatment for thrombocytopenia
Treatment for slow white blood cell recovery following chemotherapy
For the reduction in the duration of severe chemotherapy-induced neutropenia
For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura
For the treatment of anemia due to chronic kidney disease
Treatment for cholesterol-lowering
For the treatment of thrombocytopenia
Treatment of heparin-induced thrombocytopenia type II
For the control of serum phosphorus in patients with chronic kidney disease on dialysis
For the treatment of low- and intermediate-1-risk myelodysplastic syndromes
For the treatment of HIV-1 infection in combination with other antiretroviral agents
Treatment for non-hodgkin's lymphoma
For the treatment of hyponatremia
For the treatment of paroxysmal nocturnal hemoglobinuria
For the treatment of atypical hemolytic uremic syndrome
For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis
For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias
Diagnostic contrast agent
For the treatment of type 1 Gaucher disease
For the treatment of von Willebrand disease
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery
For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema
FDA Approved Hematology Drugs Listings:
The rules of principle for evaluating MediLexicon's FDA hematology drugs listings adhere to the FDA definitions of a new drug approval or a new molecular entity, and the Tufts Center for the Study of Drug Development.
MediLexicon's FDA Approved Drugs Listings include:
New Molecular Entities (NME): these NME's are described as a medication containing an active substance that have never previously approved in the US for marketing in any manner, shape or form (as defined by the FDA). In addition to this, there is also the inclusion of some FDA's Center for Drug Evaluation and Research (CDER) approved recombinant proteins and biologics.
MediLexicon's FDA Approved Drugs Listings do NOT include:
Over-the-counter products, diagnostic agents, generics, most vaccines, medical devices, biologic compounds (not approved by CDER), as well as new indications and new administrations of previously-approved compounds and new dosages.
The hematology drugs information used in this section is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
